| Detailed information |
|---|
| CancerLivER ID | 2425 |
| Biomarker | SMAD4 |
| Biomarker Name/Symbol (given in Publication) | SMAD 4 |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | Potenial Diagnostic marker for HCC; but not validated on independent patient cohort |
| Experimental Condition | HCC v/s normal |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated in HCC than normal |
| Level of significance | (R2 = 0.85) compared with HCC versus normal liver (R2 = 0.51) |
| Source | Tissue |
| PMID | 14517841 |
| Type of Biomarker | Diagnostic |
| Pathway | DNA-binding transcription factor activity |
| Cohort | 210 HCC specimens and corresponding liver tissue: 108 patients had concomitant liver cirrhosis (51%) due to HBV infection (n = 29), HCV infection (n = 23), alcohol consumption (n = 39), autoimmune disorders (n = 10), haemochromatosis (n = 2), or other (unknown) reasons (n = 5); 30 HCC patients witho |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HCC v/s normal liver |
| Year of Publication | 2003 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |